MENTAL DISORDERS OF AGING -- ANTIINFLAMMATION IN AD
衰老性精神障碍——AD 中的抗炎药
基本信息
- 批准号:8363471
- 负责人:
- 金额:$ 1.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAge-associated memory impairmentAgingAlzheimer&aposs DiseaseAnti-Inflammatory AgentsAnti-inflammatoryApolipoprotein EAtrophicAttenuatedBrain imagingDevelopmentDouble-Blind MethodEarly DiagnosisEarly treatmentElderlyEpidemiologic StudiesFundingGenetic RiskGenotypeGrantHLA AntigensHLA-A2 AntigenHippocampus (Brain)IbuprofenImmuneImpaired cognitionInflammatoryLesionMagnetic Resonance ImagingMental disordersMicrogliaModelingNational Center for Research ResourcesNeurobehavioral ManifestationsOnset of illnessPersonsPharmaceutical PreparationsPlacebosPrincipal InvestigatorRandomizedResearchResearch InfrastructureResourcesRiskSourceSymptomsTestingTreatment outcomeUnited States National Institutes of HealthWhite Matter DiseaseWorkage relatedapolipoprotein E-4brain morphologycomputational anatomycostdesignfollow-uphigh riskneuropsychologicalpreventtreatment trialvisual memory
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Several observational epidemiological studies indicate that anti- inflammatory treatments attenuate or prevent the symptoms of one of the most common mental disorders of late life, Alzheimer disease (AD). Neuropathological studies also support inflammatory or immune mechanisms in AD, including findings of reactive microglia within or near AD lesions. Such evidence, however, is circumstantial, and controlled, randomized drug trials are needed to determine efficacy. The proposed project is designed to determine if the commonly used non-steroidal anti-inflammatory drug (NSAID), ibuprofen, is efficacious in delaying progression of cognitive symptoms in people with age-related cognitive losses who are at risk for developing AD. A total of 135 subjects with age-associated memory impairment (AAMI) who are at risk for further cognitive decline (age 65 to 90 years, low scores on tests of verbal and visual memory and verbal fluency) will be randomized (double-blind design) to one of two treatment groups: ibuprofen (1200 mg/d) or placebo, and followed for two years for evidence of further cognitive decline. All randomized subjects will receive magnetic resonance imaging (MRI) scans and selective genotyping (apolipoprotein E [APOE] and human leukocyte antigen [HLA) to explore how baseline brain morphology (e.g., deep white matter disease hippocampal asymmetry and atrophy) and genetic risk for AD onset (e.g., APOE-4, HLA- A2) influence decline rates and treatment outcome. Subjects receiving ibuprofen are expected to show less evidence of cognitive decline than those receiving placebo. The proposed project builds upon our group's prior work on early detection of AD using brain imaging, genetic risk, and neuropsychological assessments. This project also is a logical follow-up to recent observation studies of a promising early intervention and will represent one of the first controlled, anti-inflammatory treatment trials for persons at high risk for age-related cognitive decline and the eventual development of AD.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
NCRR赠款不直接向子项目或子项目工作人员提供资金。
几项观察性流行病学研究表明,抗炎治疗减轻或预防老年最常见的精神障碍之一阿尔茨海默病(AD)的症状。神经病理学研究也支持AD的炎症或免疫机制,包括在AD病变内或附近发现反应性小胶质细胞。然而,这样的证据是间接的,需要对照的随机药物试验来确定疗效。拟议的项目旨在确定常用的非甾体抗炎药(NSAID)布洛芬是否能有效延缓与年龄相关的认知丧失患者的认知症状进展,这些患者有患AD的风险。共有135例年龄相关性记忆障碍(AAMI)受试者存在进一步认知下降的风险(年龄65 - 90岁,言语和视觉记忆以及言语流畅性测试得分较低),将其随机(双盲设计)分配至两个治疗组之一:布洛芬(1200 mg/d)或安慰剂,并随访2年以获得进一步认知下降的证据。所有随机化受试者将接受磁共振成像(MRI)扫描和选择性基因分型(载脂蛋白E [APOE]和人类白细胞抗原[HLA]),以探索基线脑形态学(例如,深部白色物质疾病海马体不对称和萎缩)和AD发病的遗传风险(例如,APOE-4、HLA-A2)影响下降率和治疗结果。预期接受布洛芬的受试者比接受安慰剂的受试者表现出更少的认知下降证据。该项目建立在我们小组先前使用脑成像,遗传风险和神经心理学评估早期检测AD的工作基础上。该项目也是最近一项有希望的早期干预观察研究的逻辑后续行动,并将代表针对年龄相关认知能力下降和最终发展为AD的高风险人群的首批对照抗炎治疗试验之一。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY William SMALL其他文献
GARY William SMALL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY William SMALL', 18)}}的其他基金
EFFECTS OF VULNERABILITY AND RESILIENCY ON BRAIN HEALTH DURING THE MID-TO-LATE-LIFE TRANSITION
中晚年过渡期间脆弱性和弹性对大脑健康的影响
- 批准号:
10283069 - 财政年份:2021
- 资助金额:
$ 1.01万 - 项目类别:
AMYLOID PLAQUE AND TANGLE IMAGING IN AGING AND DEMENTIA
衰老和痴呆症中的淀粉样斑块和缠结成像
- 批准号:
8363428 - 财政年份:2011
- 资助金额:
$ 1.01万 - 项目类别:
AMYLOID PLAQUE AND TANGLE IMAGING IN AGING AND DEMENTIA
衰老和痴呆症中的淀粉样斑块和缠结成像
- 批准号:
8171035 - 财政年份:2010
- 资助金额:
$ 1.01万 - 项目类别:
MENTAL DISORDERS OF AGING -- ANTIINFLAMMATION IN AD
衰老性精神障碍——AD 中的抗炎药
- 批准号:
8171156 - 财政年份:2010
- 资助金额:
$ 1.01万 - 项目类别:
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down's Syndrome and Dementia
唐氏综合症和痴呆症的葡萄糖代谢、淀粉样蛋白和 Tau 蛋白脑成像
- 批准号:
8033241 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
AMYLOID PLAQUE AND TANGLE IMAGING IN AGING AND DEMENTIA
衰老和痴呆症中的淀粉样斑块和缠结成像
- 批准号:
7955642 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
MENTAL DISORDERS OF AGING -- ANTIINFLAMMATION IN AD
衰老性精神障碍——AD 中的抗炎药
- 批准号:
7955792 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
CLINICAL TRIAL: BETA-AMYLOID PROBES OF ALZHEIMER'S DISEASE
临床试验:阿尔茨海默病的 β-淀粉样蛋白探针
- 批准号:
7951523 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down's Syndrome and Dementia
唐氏综合症和痴呆症的葡萄糖代谢、淀粉样蛋白和 Tau 蛋白脑成像
- 批准号:
7777863 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down's Syndrome and Dementia
唐氏综合症和痴呆症的葡萄糖代谢、淀粉样蛋白和 Tau 蛋白脑成像
- 批准号:
7564869 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
相似海外基金
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7606738 - 财政年份:2007
- 资助金额:
$ 1.01万 - 项目类别:
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7717960 - 财政年份:2007
- 资助金额:
$ 1.01万 - 项目类别:
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7205360 - 财政年份:2004
- 资助金额:
$ 1.01万 - 项目类别:
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6305687 - 财政年份:1999
- 资助金额:
$ 1.01万 - 项目类别:
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6115572 - 财政年份:1998
- 资助金额:
$ 1.01万 - 项目类别:
A study on the biological features of age-associated memory impairment (AAMI).
年龄相关记忆障碍(AAMI)生物学特征的研究。
- 批准号:
09671003 - 财政年份:1997
- 资助金额:
$ 1.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C).
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6276806 - 财政年份:1997
- 资助金额:
$ 1.01万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
3386469 - 财政年份:1990
- 资助金额:
$ 1.01万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
3386468 - 财政年份:1990
- 资助金额:
$ 1.01万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
2247160 - 财政年份:1990
- 资助金额:
$ 1.01万 - 项目类别: